NanoGroup S.A. (NNG.WA)

PLN 3.1

(-2.82%)

Net Debt Summary of NanoGroup S.A.

  • NanoGroup S.A.'s latest annual net debt in 2023 was -537.61 Thousand PLN , up 76.94% from previous year.
  • NanoGroup S.A.'s latest quarterly net debt in 2024 Q2 was -2.26 Million PLN , down -109.82% from previous quarter.
  • NanoGroup S.A. reported annual net debt of -2.33 Million PLN in 2022, up 37.22% from previous year.
  • NanoGroup S.A. reported annual net debt of -3.71 Million PLN in 2021, up 62.99% from previous year.
  • NanoGroup S.A. reported quarterly net debt of -1.07 Million PLN for 2024 Q1, down -100.7% from previous quarter.
  • NanoGroup S.A. reported quarterly net debt of -1.81 Million PLN for 2023 Q2, up 50.75% from previous quarter.

Annual Net Debt Chart of NanoGroup S.A. (2023 - 2014)

Historical Annual Net Debt of NanoGroup S.A. (2023 - 2014)

Year Net Debt Net Debt Growth
2023 -537.61 Thousand PLN 76.94%
2022 -2.33 Million PLN 37.22%
2021 -3.71 Million PLN 62.99%
2020 -10.03 Million PLN -689.44%
2019 -1.27 Million PLN 71.93%
2018 -4.52 Million PLN 17.75%
2017 -5.5 Million PLN 40.84%
2016 -9.3 Million PLN -133.69%
2015 -3.98 Million PLN -537.83%
2014 909.59 Thousand PLN 0.0%

Peer Net Debt Comparison of NanoGroup S.A.

Name Net Debt Net Debt Difference
Bioceltix S.A. -9.13 Million PLN 94.115%
BIOTON S.A. 64.81 Million PLN 100.83%
Captor Therapeutics Spolka Akcyjna -71.92 Million PLN 99.253%
Mabion S.A. -11.98 Million PLN 95.516%
Molecure S.A. -56.84 Million PLN 99.054%
Pharmena S.A. -22.05 Million PLN 97.563%
Poltreg S.A. -57.75 Million PLN 99.069%
Pure Biologics Spólka Akcyjna 9.33 Million PLN 105.761%
Ryvu Therapeutics S.A. -57.03 Million PLN 99.057%
Synthaverse S.A. 67.86 Million PLN 100.792%
Urteste S.A. -512 Thousand PLN -5.002%